Lucid Diagnostics Inc. (LUCD) Stock Forecast
LUCD analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $4.00 average of analyst targets
- Upside to target
- +736.8% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.05
- 52-week range
- $0.48 – $1.47
LUCD analyst ratings
5 analystsNumber of analysts at each rating.
LUCD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LUCD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.06 | −$0.05 | −$0.10 | +43.3% | 3 |
| Current fiscal year (2026) | −$0.24 | −$0.25 | −$0.24 | −$0.43 | +43.4% | 3 |
| Next fiscal year (2027) | −$0.17 | −$0.19 | −$0.14 | −$0.24 | +32.2% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LUCD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.6M | $1.5M | $1.8M | +35.5% | 5 |
| Current fiscal year (2026) | $6.3M | $5.7M | $7.0M | +33.9% | 5 |
| Next fiscal year (2027) | $16.7M | $9.9M | $23.0M | +165.2% | 5 |
LUCD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LUCD revenue: reported and forecast
LUCD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.06 | −$0.05 | −$0.05 | −$0.06 | −$0.06 | +3.1% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.26 | −$0.24 | −$0.24 | −$0.24 | −$0.24 | −4.6% | 1 up · 1 down |
| Next fiscal year (2027) | −$0.17 | −$0.17 | −$0.16 | −$0.17 | −$0.17 | −2.9% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LUCD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LUCD beat in 2 of 12.
What analysts expect from LUCD
5 analysts cover Lucid Diagnostics; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.00, 736.8% above the latest close of $0.48. Analysts expect earnings of −$0.24 per share for 2026, +43.4% from a year earlier. For 2027 the average estimate is −$0.17 per share on revenue of $16.7 million. Lucid Diagnostics beat the EPS estimate in 2 of the last 12 quarters.
Related: LUCD income statement, LUCD key metrics, LUCD chart. See the LUCD stock overview for the latest quote and news.
LUCD forecast FAQ
What is Lucid Diagnostics's price target?
The average analyst price target for Lucid Diagnostics is $4.00, 736.8% above the latest close of $0.48.
Is Lucid Diagnostics a buy, hold or sell?
Of 5 analysts covering Lucid Diagnostics, 3 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Lucid Diagnostics's EPS forecast?
Analysts forecast −$0.24 per share for 2026 (range −$0.25 to −$0.24); for 2027 the estimate is −$0.17.
What is Lucid Diagnostics's revenue forecast?
The average revenue estimate for 2026 is $6.3 million, growth of 33.9%; for 2027 it is $16.7 million.
When does Lucid Diagnostics report earnings?
Lucid Diagnostics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens; the EPS estimate is $-0.05.
Does Lucid Diagnostics usually beat earnings estimates?
Lucid Diagnostics reported EPS at or above the analyst estimate in 2 of the last 12 quarters.